RESUMO
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
RESUMO
Parasitic nematodes negatively impact human and animal health worldwide. The market withdrawal of nematicidal agents due to unfavourable toxicities has limited the available treatment options. In principle, co-administering nematicides at lower doses along with molecules that potentiate their activity could mitigate adverse toxicities without compromising efficacy. Here, we screened for new small molecules that interact with aldicarb, which is a highly effective treatment for plant-parasitic nematodes whose toxicity hampers its utility. From our collection of 638 worm-bioactive compounds, we identified 20 molecules that interact positively with aldicarb to either kill or arrest the growth of the model nematode Caenorhabditis elegans. We investigated the mechanism of interaction between aldicarb and one of these novel nematicides called wact-86. We found that the carboxylesterase enzyme GES-1 hydrolyzes wact-86, and that the interaction is manifested by aldicarb's inhibition of wact-86's metabolism by GES-1. This work demonstrates the utility of C. elegans as a platform to search for new molecules that can positively interact with industrial nematicides, and provides proof-of-concept for prospective discovery efforts.
Assuntos
Aldicarb/farmacologia , Antinematódeos/farmacologia , Benzamidas/farmacologia , Benzofuranos/farmacologia , Proteínas de Caenorhabditis elegans/genética , Caenorhabditis elegans/efeitos dos fármacos , Hidrolases de Éster Carboxílico/genética , Nematoides/efeitos dos fármacos , Sequência de Aminoácidos , Animais , Antinematódeos/química , Proteínas de Caenorhabditis elegans/antagonistas & inibidores , Hidrolases de Éster Carboxílico/antagonistas & inibidores , Mutação , Alinhamento de SequênciaRESUMO
BACKGROUND: Data on predictors of decline in PD are largely based on de-novo populations and limited to the use of motor outcomes that fail to capture the full scope of disease. OBJECTIVE: Determine the clinical predictors of decline in early treated PD using a novel multi-domain measure. METHODS: Data from NINDS Exploratory Trials in PD Long-Term Study 1 (NET-PD LS1), a multicenter Phase 3 study of creatine in early treated PD, were analyzed. Functional decline was defined by a global outcome metric (GO) that consisted of: Schwab and England ADL scale, PD 39-item Questionnaire, Unified PD Rating Scale, Ambulatory Capacity Score, Symbol Digit Modalities Test, and Modified Rankin Scale. Univariate and multivariate models were used to test the association of predictors of interest with a standardized rank-sum of the GO. RESULTS: 765 of 1741 participants completed five-year assessments and were included. Older age at disease onset (pâ< â0.0001), higher baseline levodopa equivalent dose (pâ=â0.01), and worse Scales for Outcomes of Parkinson's Disease Cognition score (pâ=â0.001) at baseline were the strongest predictors of functional decline in multivariate analysis. PD symptom subtype was not a significant predictor of outcome (pâ=â0.42). The full model was only a modest predictor of change in GO (R2â=â0.186). CONCLUSIONS: This is the largest study to systematically assess predictors of functional decline in early treated PD over several years, and the first to use a multi-domain outcome measure of decline. Older age at disease onset and worse cognition, and not PD subtype, were predictors of decline.
Assuntos
Antiparkinsonianos/administração & dosagem , Progressão da Doença , Avaliação de Resultados em Cuidados de Saúde/métodos , Doença de Parkinson/diagnóstico , Índice de Gravidade de Doença , Atividades Cotidianas , Idade de Início , Idoso , Feminino , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , National Institute of Neurological Disorders and Stroke (USA) , Doença de Parkinson/tratamento farmacológico , Prognóstico , Estados UnidosRESUMO
Parasitic nematodes infect one quarter of the world's population and impact all humans through widespread infection of crops and livestock. Resistance to current anthelmintics has prompted the search for new drugs. Traditional screens that rely on parasitic worms are costly and labour intensive and target-based approaches have failed to yield novel anthelmintics. Here, we present our screen of 67,012 compounds to identify those that kill the non-parasitic nematode Caenorhabditis elegans. We then rescreen our hits in two parasitic nematode species and two vertebrate models (HEK293 cells and zebrafish), and identify 30 structurally distinct anthelmintic lead molecules. Genetic screens of 19 million C. elegans mutants reveal those nematicides for which the generation of resistance is and is not likely. We identify the target of one lead with nematode specificity and nanomolar potency as complex II of the electron transport chain. This work establishes C. elegans as an effective and cost-efficient model system for anthelmintic discovery.
Assuntos
Anti-Helmínticos/farmacologia , Caenorhabditis elegans/efeitos dos fármacos , Animais , Anti-Helmínticos/química , Caenorhabditis elegans/genética , Proteínas de Caenorhabditis elegans/genética , Proteínas de Caenorhabditis elegans/metabolismo , Resistência a Medicamentos/genética , Complexo II de Transporte de Elétrons/antagonistas & inibidores , Complexo II de Transporte de Elétrons/metabolismo , Células HEK293 , Humanos , Modelos Moleculares , Estrutura Molecular , Filogenia , Conformação Proteica , Especificidade da Espécie , Relação Estrutura-Atividade , Peixe-ZebraRESUMO
Nicorandil is a vasodilator used to control angina. It has been associated with oral ulceration and stomatitis that resolves upon withdrawal of the drug. We report a series of five patients with non-specific anal ulceration, all of whom received nicorandil for symptomatic control of ischaemic heart disease. Histological appearances were similar and the ulcers healed on withdrawal of the drug. Our results suggest that nicorandil might be a cause of anal ulceration.